Follow
Vivek Subbiah, MD
Vivek Subbiah, MD
Associate Professor, The University of Texas MD Anderson Cancer Center
Verified email at mdanderson.org
Title
Cited by
Cited by
Year
Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations
DM Hyman, I Puzanov, V Subbiah, JE Faris, I Chau, JY Blay, J Wolf, ...
New England Journal of Medicine 373 (8), 726-736, 2015
18342015
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet 395 (10241), 1907-1918, 2020
18052020
Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer
V Subbiah, RJ Kreitman, ZA Wainberg, JY Cho, JHM Schellens, JC Soria, ...
Journal of Clinical Oncology 36 (1), 7, 2018
7782018
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ...
New England Journal of Medicine 383 (9), 813-824, 2020
6562020
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
LJ Wirth, E Sherman, B Robinson, B Solomon, H Kang, J Lorch, F Worden, ...
New England Journal of Medicine 383 (9), 825-835, 2020
5932020
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease
C Fermé, H Eghbali, JH Meerwaldt, C Rieux, J Bosq, F Berger, T Girinsky, ...
New England Journal of Medicine 357 (19), 1916-1927, 2007
5602007
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
V Subbiah, JF Gainor, R Rahal, JD Brubaker, JL Kim, M Maynard, W Hu, ...
Cancer discovery 8 (7), 836-849, 2018
3732018
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
V Subbiah, U Lassen, E Élez, A Italiano, G Curigliano, M Javle, ...
The Lancet Oncology 21 (9), 1234-1243, 2020
3672020
Selective RET kinase inhibition for patients with RET-altered cancers
V Subbiah, V Velcheti, BB Tuch, K Ebata, NL Busaidy, ME Cabanillas, ...
Annals of Oncology 29 (8), 1869-1876, 2018
3542018
Vemurafenib for BRAF V600–mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study
EL Diamond, V Subbiah, AC Lockhart, JY Blay, I Puzanov, I Chau, ...
JAMA oncology 4 (3), 384-388, 2018
3482018
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
J Trigo, V Subbiah, B Besse, V Moreno, R López, MA Sala, S Peters, ...
The lancet oncology 21 (5), 645-654, 2020
3212020
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
JF Gainor, G Curigliano, DW Kim, DH Lee, B Besse, CS Baik, ...
The lancet oncology 22 (7), 959-969, 2021
3072021
Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells
C Tang, JW Welsh, P De Groot, E Massarelli, JY Chang, KR Hess, S Basu, ...
Clinical Cancer Research 23 (6), 1388-1396, 2017
2982017
BRAF inhibition in BRAFV600-mutant gliomas: results from the VE-BASKET study
T Kaley, M Touat, V Subbiah, A Hollebecque, J Rodon, AC Lockhart, ...
Journal of Clinical Oncology 36 (35), 3477, 2018
2832018
Cancer therapy directed by comprehensive genomic profiling: a single center study
JJ Wheler, F Janku, A Naing, Y Li, B Stephen, R Zinner, V Subbiah, S Fu, ...
Cancer research 76 (13), 3690-3701, 2016
2532016
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
V Subbiah, MI Hu, LJ Wirth, M Schuler, AS Mansfield, G Curigliano, ...
The lancet Diabetes & endocrinology 9 (8), 491-501, 2021
2482021
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
S Kato, V Subbiah, E Marchlik, SK Elkin, JL Carter, R Kurzrock
Clinical Cancer Research 23 (8), 1988-1997, 2017
2432017
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
DS Hong, VK Morris, B El Osta, AV Sorokin, F Janku, S Fu, MJ Overman, ...
Cancer discovery 6 (12), 1352-1365, 2016
2322016
Clinical development of BRAF plus MEK inhibitor combinations
V Subbiah, C Baik, JM Kirkwood
Trends in cancer 6 (9), 797-810, 2020
2132020
RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies
BJ Solomon, L Tan, JJ Lin, SQ Wong, S Hollizeck, K Ebata, BB Tuch, ...
Journal of Thoracic Oncology 15 (4), 541-549, 2020
2122020
The system can't perform the operation now. Try again later.
Articles 1–20